Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized catheter plan aims to cut Re-Insertions after rectal cancer surgery

NCT ID NCT07346586

Not yet recruiting Symptom relief Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a personalized plan for removing urinary catheters after mid-low rectal cancer surgery can reduce the need for re-insertion. About 1,545 patients will be randomly assigned to one of three groups: catheter removal at 24 hours, at 48 hours, or an individualized plan where high-risk patients get a medication (tamsulosin) before removal. The main goal is to see which strategy leads to the fewest patients needing a new catheter within a week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tamsulosin
What this could lead to
If successful, this could lead to a standard, personalized plan for removing urinary catheters earlier after rectal cancer surgery, reducing discomfort and infection risk.
What could go wrong
This is a single-center trial that hasn't started yet. The results may not apply to all hospitals, and the personalized approach may not lower re-catheterization rates as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm Urinary Retention

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER URINARY CATHETERS URINARY RETENTION

Contacts and locations

Locations

  • The First Hospital of Jilin University

    Changchun, Jilin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.